t-loop

YKL-5-124, a potent, selective and covalent CDK7 inhibitor with an IC50 of 9.7 nM, 1300 nM and 3020 nM for CDK7/Mat1/CycH, CDK2 and CDK9 respectively, displays biochemical and cellular selectivity for CDK7 over CDK12/13.

FKB04 is a telomeric repeat binding factor 2 (TRF2) inhibitor that exerts its antitumor activity by disrupting the telomere maintenance mechanisms in hepatocellular carcinoma cells. This leads to T-loop defects, inducing telomere shortening and cellular senescence. Additionally, FKB04 inhibits tumor growth in a human liver cancer xenograft mouse model (by implanting Huh-7 cells in BALB/c mice). This compound is utilized in research focused on liver cancer.

Zinlirvimab (10-1074) is a humanized IgG1-λ2 monoclonal neutralizing antibody that targets the gp120/CD4 interface on the HIV-1 envelope glycoprotein receptor to effectively prevent viral attachment. Zinlirvimab (10-1074) inhibits the complex process of viral entry into host CD4+ T cells by recognizing and binding to specific conserved epitopes, thereby effectively preventing the Human Immunodeficiency Virus from establishing a productive and systemic infection. Zinlirvimab (10-1074) exhibits a remarkably optimized pharmacological profile with a significantly extended half-life through specialized Fc-region modifications, facilitating its role as a persistent agent for sustained viral suppression.